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Abstract
Purpose A large number of medications have been implicated
in the genesis of gynecomastia. However, gynecomastia is
common in men, asymptomatic, increases with age, and is
considered to be due to an increased estradiol/testosterone
ratio. This complicates the interpretation of medication-
related gynecomastia. Therefore, we have reviewed the liter-
ature in order to assess the data relating gynecomastia onset
with utilization of specific medications.
Methods The literature was searched in PubMed and the
Ovid/Medline databases from the 1946 to January 2015 with
the search terminology of Bgynecomastia, drugs/
medications.^ A few other articles were found and included.
Results One hundred ten publications were reviewed. Sixty-
three were single case reports. There were 24 population-
based studies of which 8 were HIV-infected patients treated
with antiretroviral agents. Among the case reports, 49 were for
individual medications, and 2 were reports of antineoplastic or
antiretroviral drug regimens. In the great majority, mastodynia
with or without breast enlargement was present and referred to
as gynecomastia. Generally, hormonal profiles could not ex-
plain the breast enlargement. The pain/tenderness and breast
enlargement resolved spontaneously over time.
Conclusion Many different medications have been associated
with the presence of Bgynecomastia.^ Generally, it presents as
a syndrome characterized by a single painful/tender breast
(mastodynia) associated with breast enlargement and is tran-
sient. We suggest that these cases be referred to as an acute
gynecomastia syndrome. This syndrome also occurs indepen-
dent of medication use. Thus, in an individual patient, whether
it is medication induced often remains uncertain. The patho-
genesis remains unknown.
Keywords Spironolactone .Mastodynia . Gynecomastia .
Andromastia
Introduction
Gynecomastia, as currently defined, represents the presence of
palpable, subareolar breast tissue with a diameter of 2 cm or
greater. Generally, it is asymptomatic, not noted by the pa-
tients, and the prevalence increases with aging and obesity
[1]. The etiology is uncertain but has been attributed to an
increase in the estradiol/testosterone ratio [2, 3].
Numerous medications have been reported to be associated
with the development of gynecomastia. The implication is that
these drugs were responsible for its appearance or progression
and this is due to a change in the sex hormone status. In this
review, we have systematically searched the literature regard-
ing drugs suspected to be etiologically related to the clinical
manifestation of breast enlargement, i.e., the development of
gynecomastia. Drug implications are particularly important
because it has been clearly shown that gynecomastia, as de-
fined above is asymptomatic, and a common finding in males.
Indeed, the prevalence has been reported to be 36 % in youn-
ger adult males (17–58 years) and to be present in more than
50 % in men over 44 years of age [1]. In a group of
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hospitalized patients, ages 58 to 71 years, the mean prevalence
was 65 %, and it increased with age and body mass index
(BMI). With a BMI of 25 or greater, the prevalence was
~80 % [4]. Since the prevalence of palpable breast tissue
(PBT) is so high, usually bilateral, and nearly always asymp-
tomatic, the administration of a drug and the concurrent de-
tection of gynecomastia could be purely coincidental, or more
likely if pain/tenderness (mastodynia) is present the breast
enlargement represents an independent (unique) syndrome,
the etiology of which may or may not be related to a specific
drug. This would particularly be the case if it is unilateral.
We have reviewed the English language literature from
1946 to January week 4, 2015 in an attempt to determine the
types of data that frequently are included in reviews as indic-
ative of drug-induced development of gynecomastia.
Methods
Originally, the literature was searched in PubMed and the
Ovid databases from the 1950s to April 2012 with the search
terminology of Bgynecomastia, drugs/medications.^ Eighty-
five publications were identified and were used in the review.
Fourteen additional articles were found and added to the list
for a total of 99. Seventy-six were case reports. Seven were
series of HIV-infected patients treated with antiretroviral reg-
imens. There were nine reports of population-based studies
(prospective or retrospective). Subsequently, at the recom-
mendation of one of the reviewers, the literature was search
again using Ovid/Medline and PubMed for each of the 49
individual drugs listed in Table 1, crossed with the term gy-
necomastia. The date range of the search was 1946 to January
2015. From this search, we added 22 new cases, referred to in
9 additional references.
Publications of an association with a drug no longer used,
such as digitalis, and methyl-dopa, were not reviewed. We did
not attempt an exhaustive review of the literature or of
postmarketing reports of gynecomastia as an adverse effect
of medications such as in the Food and Drug Administration
(FDA-Medwatch) database. How gynecomastia is defined
and ascertained is not readily available in these publications.
Medications known to cause androgen deficiency, e.g., GnRH
agonists and high-dose ketoconazole (600 mg/day or greater),
were not included.
In this review, we attempted to determine (1) how the diag-
nosis was made; (2) the presence or absence of mastodynia; (3)
whether the Bgynecomastia^ was unilateral or bilateral; (4)
whether hormonal studies were done, i.e., testosterone/
estradiol data; and (5) whether either the testosterone was low,
the estradiol high, or the estradiol/testosterone ratio was abnor-
mal. We also determined whether (6) a remission or disappear-
ance of the mastodynia and/or breast Bswelling^ occurred over
time and (7) whether a drug rechallenge test was done. Last, (8)
Table 1 Medications reported to be associated with the appearance of
gynecomastia
Drug Reference
1 Amlodipine [5*, 6]
2 Atorvastatin [7]
3 Benserazide [8]
4 Captopril [9, 10]
5 Cimetidine [11–15]
6 Cladribine [16]






13 Digoxin [30, 31]




18 Efavirenz (HIV) [37–39*]
19 Fenofibrate [40]
20 Finasteride [41*, 42*, 43*, 44, 45*, 46, 47]
21 Fluoresone [48*]
22 Fluoxetine [49, 50]
23 Gabapentin [51]
24 HAART^^ [52–56*, 57–62]
25 Imatinib [63*, 64]
26 Indinaver (HIV) [65, 66*]
27 Isoniazid [67–71]
28 Ketoconazole [72*, 73]
29 Marinol [74]
30 Methotrexate [75, 76]
31 Metronidazole [77]
32 Nettle [78]
33 Nifedipine [32, 79*]
34 Omeprazole [80, 81]
35 Paroxetine [82]
36 Phenytoin [48*, 83, 84*]
37 Pregabalin [85*]
38 Ranitidine [86]
39 Rosuvastatin [87, 88]
40 Saquinavir (HIV) [89*, 90]
41 Spironolactone [13, 29, 91–99]





47 Thalidomide [105, 106]
48 Theophylline [107]
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ultrasound, (9) computed tomography (CT), and (10) histolog-
ical data were recorded. It should be noted that with use of these
procedures, a diagnosis of Bgynecomastia^ generally was made
based merely by the presence or absence of breast tissue.
In addition, information available on the prevalence and
characteristics of the reported gynecomastia in some
population-based studies were reviewed.
The inclusion criteria were as follows: (1) any case report in
which the data were sufficient for us to evaluate under the
headings on Table 2, (2) Publications were in English, and (3)
publications were available through the Veterans Administra-
tion or University of Minnesota library systems. The only ex-
clusion criterion was references in which the data were insuffi-
cient for analysis.
Results
The medications reported to be associated with the appearance
of gynecomastia are indicated in Table 1. There were 49 differ-
ent medications implicated. In addition, some antineoplastic
and antiretroviral regimens were reviewed. A total of 159 cases
were reported and reviewed. There were 63 single case reports.
More than one case was reported in 24 publications. There were
24 population-based studies of which 8 were highly active an-
tiretroviral therapy (HAART)-treated patients with human im-
munodeficiency virus (HIV) infections.
The 49 single medications and the two combination regi-
mens implicated in the genesis of gynecomastia and the refer-
ences are indicated in Table 1.
Analysis of case reports (Table 2)
Diagnosis of gynecomastia
How the diagnosis of Bgynecomastia^was made was stated in
133 cases.
In 77 % of the cases, the patient experienced mastodynia
and then noted a Bswelling^ of the breast. The patient
commented on this to the provider who then initiated an eval-
uation. In the remaining cases, an increase in breast mass was
mentioned by the patient or the provider. Most commonly, the
patient mentioned an enlargement, and the provider merely
confirmed it visually or by a superficial examination.
Mastodynia
The presence of pain or tenderness was reported in 104 cases
(79 %). In 28 cases, a comment was not made regarding the
presence or absence of mastodynia.
Unilateral gynecomastia
In the 141 cases in which it was determined, it was unilateral





50 Verapamil [32*, 13]
51 Vincristine [109*]
* Indicates more than 1 case
^^ Highly Active Antiretroviral Therapy
Table 2 Analysis of case reports
Category Yes** No Unknown Total Ratio %
Y + N Yes/No Yes/(Yes+No)
Pain/tenderness @ Dx * 103 30 26 159 133 3.4 77 %
Mastodynia ± 104 27 28 159 131 3.9 79 %
Unilateral 84 57 18 159 141 1.5 60 %
Hormones Checked 91 63 5 159 154 1.4 59 %
Hormones wnl ^ 74 17 91 91 4.4 81 %
Remission 100 19 40 159 119 5.3 84 %
Rechallenge 11 148 159 159 0.07 7 %
Ultrasound 21 138 159 0.15 13 %
Mammography 46 113 159 0.41 29 %
Histology 22 137 159 0.16 14 %
* Presenting complaint by the patient
** Yes indicates that category was present and/or observed
± Noted by patient and/or the health care provider
^ Within normal limits
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Hormonal profile
A hormonal profile (testosterone, estrogen concentrations)
was reported in 91 cases. They were within the reference
range in 74 (81 %).
Remission
In 119 cases where it was commented on, a remission oc-
curred in 100 (84 %).
Rechallenge test
A rechallenge test was done in 11 of the case studies. In all 11,
a recurrence of breast enlargement and/or mastodynia was
reported after the drug was restarted. The drugs involved were
nifedipine [32], sunitinib [103], isoniazid [67], fenofibrate
[40], metronidazole [77], ranitidine [86], finesteride [41]
(two subjects), methotrexate [110], omeprazole [111], and
amlodipine [5]. A proposed mechanism in each case was not
presented. In one report when the patient was restarted on
metronidazole [77], he complained of bilateral breast tender-
ness within 3 weeks of restarting therapy, and the drug was
stopped. Palpable breast tissue had not occurred.
Ultrasonography/mammography
Among the single case reports, Bgynecomastia was
confirmed^ in 21 reports by ultrasonography (13 %). It was
Bconfirmed^ by mammography in 46 cases (29 %).
Histology
Histological data were obtained in 22 cases (14 %). Only a
fine needle aspiration was done in 9 of these cases. Often, the
objective was to rule out a malignancy.
In this regard, a retrospective histological evaluation for
gynecomastia was published several years ago [112]. In a
review of 351 patients with histologically proven gynecomas-
tia, 335 of which were surgical specimens, there were 103
patients whose etiologies were considered to be idiopathic.
Of these, the gynecomastia was unilateral in all but 10
(90 %). In 38 patients whose gynecomastia was suspected to
be drug induced, 22 were bilateral (58 %). However, this
included patients treated with hormones as well. Although
not quantified, the majority of patients presented with pain
or breast tenderness. The authors commented that idiopathic
and Bdrug induced^ gynecomastia tended to be more com-
monly unilateral whereas in those with a presumed hormonal
etiology it was bilateral.
A florid-type histological appearance wasmore common in
those who had gynecomastia for 4 months or less. Also,
Bmastitis^ was observed nearly exclusively in those subjects
categorized with florid-type histology [112].
Population-based reports
Eight publications in which gynecomastia had been reported
in patients with human immunodeficiency virus (HIV) infec-
tions receiving (highly active antiretroviral therapy) HAART
treatment will be reviewed only briefly. The results are shown
in Table 3. In general, the prevalence was either not indicated
or was lower than expected in the general population. Also,
whether the noted breast enlargement was new or not is some-
times difficult to determine. However, in the great majority, it
was unilateral, frequently presented with pain/tenderness, and
in general was not associated with a hormonal abnormality
when this was determined. Thus, the characteristics of the
reported gynecomastia were similar to those reported with a
variety of other single medications. As with the single medi-
cations, the role of the HAART treatment, if any, in the genesis
of Bgynecomastia^ is uncertain.
Of interest, in reference [52], spontaneous resolution oc-
curred in 20 of 21 patients monitored for more than 1 year in
spite of continuing the HAART regimen. Also, two cases have
been reported in HIV-infected men that were not attributed to
medications [53].
Cohort studies analyzed by specific medication
Ketoconazole
There were several publications of an association of gyneco-
mastia with ketoconazole. However, only two publications of
the same three patients who met our criteria were found. In 40
patients being treated for a fungal infection with ketoconazole
(200–400 mg/day), 3 complained of mastodynia, and bilateral
gynecomastia was detected by physical examination after 3–
6 weeks of treatment [72]. The examination technique was not
specified. Hormonal studies were done in two patients and
were within normal limits. A rechallenge was not done. Later,
the same authors reported data on 60 patients, but there was no
further increase in patients with gynecomastia [73].
Imatinib
In a carefully done prospective study of 38 men being treated
with imatinib for chronic myeloid leukemia, breast mass
changes were determined by direct sequential measurement
[63]. Seven patients developed palpable breast tissue equal
to or greater than 2 cm in diameter. The treatment itself tended
to be associated with reduction in the free and total testoster-
one concentration in all of the subjects, but the decrease was in
general greater in those who developed breast enlargement.
Estradiol data apparently were obtained but not reported. The
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number reporting pain or tenderness was not indicated, but it
was stated to have occurred often. Also, whether the breast
enlargement was unilateral or bilateral was not stated. How-
ever, in at least one case, it was unilateral. A rechallenge was
not done.
In a subsequent series of 44 patients being treated for a
gastrointestinal stromal tumor, six developed a Bpainful lump
under bilateral nipples^ [64] which measured 2.5 to 5 cm.
Testosterone was within the reference range, but the estradiol
was modestly elevated in three patients. Over time, the Bbreast
lesions^ decreased in size in three and disappeared completely
in two [64].
Cimetidine
There are several reports of an association of cimetidine with
gynecomastia. Only three are reviewed here as typical of the
data. In the first study [11], cimetidine, 1.6 gm daily, was
administered to 25 patients with gastric symptoms. After treat-
ment for 4–9 months, five patients reported soreness of one or
both nipples, associated with breast swelling. How gyneco-
mastia was confirmed was not indicated. Testosterone and
estradiol were within the reference range. A rechallenge was
not done.
In the second study [12], cimetidine was administered to 22
patients for Bgastric hypersecretory states.^ The typical dose
was reported to be 3.5-fold (5.3 g daily) greater than a typical
dose used to treat peptic ulcer disease. Nine complained of
breast changes, 8 of which noted increased nipple sensitivity
or breast pain. Gynecomastia was reported in 5. However,
how the diagnosis was documented is unclear. Hormonal stud-
ies were not done. A rechallenge was not done.
The prevalence of gynecomastia also was reported in 81,
535 males using data obtained from UK general practitioners,
who agreed to provide data on patients being treated with
proton pump inhibitors/antacids (cimetidine, misoprostol,
omeprazole, or ranitidine) [13]. New onset gynecomastia
was reported in 153. The gynecomastia was attributed exclu-
sively to the use of cimetidine and was dose dependent. Infor-
mation for 80 of these cases was available. In this group, 67
were self-reported, and 11 were incidental findings. Data were
not available in two cases.Whether the patients presented with
mastodynia was not stated. Thirty-four were unilateral, 38
were bilateral, and in 8, this information was lacking. In 37,
there was complete regression, and it was partial in 14. Hor-
monal studies were not done. A rechallenge was not done. The
gynecomastia was attributed to a cimetidine induced increase
in estradiol due to impaired conversion to the inactive 2-
hydroxy-estradiol product, as reported by Galbraith and
Michnovicz [114]. However, as indicated above, hormone
data were not obtained and based on the data obtained in
reference [11], this explanation is unlikely.
Cimetidine is not commonly used at present, particularly in
the doses used in the past. It is available over the counter in
smaller dose sizes in the USA, and to our knowledge, an
association of gynecomastia with cimetidine has not been
Table 3 Subjects with HIV
Study type Total # # w/ Gyneco-
mastia





Most visually. Not done
Population L.Piroth
et al. [58]
239 6 First observed by patients; confirmed
by Bclinical investigation.^
FSH, LH, TSH, cortisol within reference







Diagnosis made if all the following
were present:
1) Patient noted enlargement
2) Examination done
3) Ultrasound
Nested control comparison done (n=30)
bioavailable testosterone lower, free





(4 unilateral), 9 presented
with tenderness/pain
Diagnosis made by patient.
Observation followed by
ultrasound.
Hormone data not reported. Stated that





in 27 of 47. PBT present
in only half
ND Testosterone levels documented
to be low in 4 subjects.
Population Allen
et al. [113]









ND not determined, PBT palpable breast tissue
Rechallenge not done in any
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reported in the last 10 or more years. This is as expected since
in the postmarketing surveillance of 763 patients treated with
cimetidine, the overall prevalence of Bgynecomastia^ was
0.2 % (quoted in reference [12]).
In summary, although cimetidine is rarely used in USA at
the present time, data obtained in the past suggest that cimet-
idine in high doses can induce nipple tenderness, mastodynia,
and transient breast swelling.
Omeprazole
In a retrospective review of cases of gynecomastia from the
BSpanish Pharmacovigilance system^ [80], 24 patients on
treatment with omeprazole were identified as having gyneco-
mastia in the 2007 year database. Here, the relative odds ratio
for omeprazole exposure showed a statistically significant el-
evation in comparison to those with no exposure. However,
how the gynecomastia was diagnosed and characterized was
not reported.
Spironolactone
The presence or development of gynecomastia has been re-
ported in several publications. Only representative reports are
included here.
In a prospective study [91], 9 subjects received 400 mg of
spironolactone for 24 weeks. Six developed gynecomastia. In
none was the diameter more than 2 cm. In the same report,
nine additional subjects received 100 mg for 4 weeks, then
400 mg for another 4 weeks. In none of these subjects did
gynecomastia develop. Whether the breast enlargement
regressed is unknown. One subject dropped out because of
painful gynecomastia.
In the second prospective study [92], spironolactone or
potassium canrenoate (a product of spironolactone metabo-
lism) was administered to 44 subjects with liver cirrhosis
and ascites. Fourteen received 100 mg/day of spironolactone
and 30 received 100 mg/day of potassium canrenoate. All of
those receiving spironolactone developed gynecomastia. Gy-
necomastia developed in 16 of the 30 who received potassium
canrenoate. Here, gynecomastia was defined as a palpable,
discrete button of firm subareolar tissue at least 2 cm in diam-
eter. Whether the palpable breast tissue was new or associated
with pain/tenderness cannot be determined from the publica-
tion. In this study, the testosterone, dialyzable testosterone,
estradiol, LH, FSH did not change significantly.
In a case control study [93], 16 subjects were studied, 6 of
whom received spironolactone and 10 were matched controls.
All of those receiving spironolactone complained of breast
swelling but apparently not pain/tenderness. All had been on
200–400 mg of spironolactone for 4 to 13 months before the
study. Gynecomastia did not develop in the ten controls. The
blood testosterone levels were significantly less and blood
estradiol levels significantly greater in the spironolactone
group, suggesting that spironolactone does alter peripheral
metabolism of testosterone in some men and results in chang-
es in the ratio of testosterone to estradiol. After withdrawal of
the spironolactone, Bthe gynecomastia disappeared.^
It should be noted that the doses of spironolactone used in
the above studies were greater than those commonly used
clinically.
The presence or development of gynecomastia also has
been reported retrospectively in several large studies. In the
randomized aldosterone evaluation trial, self-reported gyneco-
mastia occurred in 1 % of patients receiving a placebo but in
9 % receiving 25 mg of spironolactone [94]. In another retro-
spective study, the prevalence of gynecomastia was 13 %
among 699 men treated for hypertension with spironolactone,
the prevalence also was highly dose dependent. In those re-
ceiving greater than 150 mg/day, the prevalence was 52 %.
Unfortunately, how the gynecomastia was detected and de-
fined was not stated [95]. In another retrospective analysis of
an open-label study, the reported prevalence of gynecomastia
or breast discomfort was 6 % in patients when on doses of 25–
50 mg/day [115]. Again, how gynecomastia was diagnosed
was not stated.
Finally, in a retrospective study of 13,349 hospital-
ized medical patients monitored in a drug surveillance
program, 788 of whom received spironolactone during 1
or more admissions, gynecomastia as an adverse reac-
tion was reported in only 1.2 % [96]. In another retro-
spective study of 699 men receiving spironolactone
alone or in association with another antihypertension
treatment, gynecomastia was reported to occur in 13 %
but was dose related [95].
The mechanism by which spironolactone induces modest
gynecomastia remains unknown. It is speculated that
spironolactone or a metabolic product of spironolactone
[116] binds to the androgen receptors and displaces testoster-
one. Thus, spironolactone may act as a competitive inhibitor
of androgen action. Indeed, it is used to reduce sexual hair
growth in hirsute women with and without the polycystic
ovary syndrome [117]. However, Stripp et al. [97] report that
there is no plausible mechanism to explain spironolactone
induced gynecomastia, as the drug has been shown to cause
changes only in progesterone and 17-hydroxyprogesterone
values.
A treatment regimen for myeloma
In this retrospective study [20], during 1975–1979, nine pa-
tients diagnosed with myeloma were treated with a cyclophos-
phamide, prednisolone, and melphalan regimen. Four patients
who developed gynecomastia were considered to be cases,
whereas 5 who did not were considered to be controls. Gy-
necomastia was predominantly bilateral. How the
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gynecomastia was diagnosed was not indicated. An increase
in free estradiol and a relative decrease in testosterone were
only present in those with gynecomastia. Gynecomastia as a
side effect of this regimen has not been reported since.
Discussion
This review of the literature documents an extraordinary num-
ber and assortment of drugs reported to be associated with the
diagnosis of gynecomastia. Most are only single case reports
or small series. In the great majority of cases, the initial ob-
servation was by the patient and consisted of a painful or
tender breast followed by a reported enlargement of the breast.
Also, most commonly only a single breast was involved, al-
though in some, it became bilateral later in the course. Also in
nearly all cases, the pain/tenderness and the breast Bswelling^
resolved over time without specific treatment. Indeed, the
breast enlargement was often described as disappearing
completely. When determined, a hormonal etiology generally
could not be documented, although speculated on frequently.
Ultrasound and/or computed tomography (CT) has been
used to confirm the presence of gynecomastia. However, these
data generally only indicate the presence or absence of detect-
ible breast tissue. Whether it is new or not cannot be readily
determined. The latter issue also is a limitation in interpreting
breast histology. Although Bflorid^ and Bfibrotic^ histological
criteria have been used to estimate the acuity of breast enlarge-
ment [118], this has not been well documented. In addition, in
some reports, an inflammatory component has been men-
tioned [112, 119, 120]. An increase in hyaluronic acid also is
commented on, suggesting the presence of stromal edema
[120].
As reviewed above, mastodynia with the subsequent obser-
vation of breast swelling has been reported to be associated
with numerous medications. However, mastodynia associated
with or without a documented acute enlargement of the breast
occurs in men not receiving any medication.
For example, Bidiopathic gynecomastia^ was reported in
52 healthy men in the military [121]. All presented with breast
tenderness and 15 complained of pain. In 41, breast enlarge-
ment was unilateral (79 %). A spontaneous remission in ten-
derness and breast size occurred over time. Thus, the
Bgynecomastia^ in these men not receiving any medication
was very similar to that reported to be associated with specific
medications listed in Table 1.
As with the medication-associated reports, these signs and
symptoms also suggest the presence of an acute syndrome and
not the traditionally described chronic, asymptomatic gyneco-
mastia. It also should be noted that in the above report [121],
1300 young military men requested surgical treatment for
symptomatic gynecomastia over a 15-year period (an average
of 87 cases/year).
Overall, current data suggest that for most drugs, their im-
plication in the genesis of palpable breast tissue remains spec-
ulative. Although limited in scope, data implicating very high-
dose cimetidine in the genesis are compelling [11, 12]. Ima-
tinib also may induce breast enlargement, but the circum-
stances in which it is used complicate interpretation [63, 64].
Also, in a few case reports, a rechallenge test was done and
was positive. In these reports, a cause and effect relationship
probably was present. However, it likely represents an idio-
syncratic response and was not hormonally mediated, since
the medications involved have been widely used, but
mastodynia and/or breast enlargement rarely been have report-
ed. Again, the potential mechanism remains unknown.
Regardless of an unidentified mechanism, the high fre-
quency of mastodynia and of single breast involvement asso-
ciated with reports of drug-induced gynecomastia is impres-
sive. These observations make it difficult to attribute their
genesis to a circulating hormonally mediated mechanism,
and indeed, in the majority of cases the hormone profile was
within the respective reference ranges.
Spironolactone is an exception. That spironolactone ad-
ministration can induce breast enlargement when ingested in
high doses is well documented, and although the mechanism
remains uncertain, it does appear to be hormonally mediated,
i.e., an induced end result of an imbalance in the functionally
mediated ratio of estradiol/testosterone. Again, the data are
limited, but they suggest that the breast enlargement more
commonly is bilateral and not frequently associated with the
presence of pain and/or clinically significant tenderness, i.e.,
the data for spironolactone are more compatible with a hor-
monally mediated mechanism than that observed with other
medications.
This also may be the case with the administration of cyto-
toxic agents for malignancies. Of a total of 21 cases associated
with different medications and where the estradiol and/or the
testosterone changes potentially could explain the onset of
gynecomastia, cytotoxic agents were involved in 15. In addi-
tion, one was associated with finasteride where one might
expect hormonal abnormalities.
Overall, we suggest that the general term of gynecomastia
be replaced with more specific and descriptive terminology.
Initially, we suggest that the term gynecomastia or preferably
andromastia be divided into two large categories: acute with
or without mastodynia and chronic.
Conclusion
In conclusion, whether most of the medications implicated in
the genesis of gynecomastia represent a true cause and effect
relationship remains unknown. Most commonly, the syn-
drome presents as a unilateral onset of pain and/or tenderness
followed by a reported enlargement of the breast. Generally, a
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hormonal etiology cannot be implicated. The symptoms and
the breast enlargement spontaneously regress or disappear en-
tirely, and no specific treatment or further evaluation is re-
quired. This includes ultrasound, mammogram, and biopsy.
Generally, it can be treated symptomatically and not interfere
with the continued use of the drug, if the latter is considered to
be necessary.
The breast enlargement associated with the use of
spironolactone is different. It is commonly bilateral, not asso-
ciated with pain or tenderness, is dose dependent and is hor-
monally mediated, i.e., it likely represents an acute onset of
traditional gynecomastia.
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